Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2021

Aug 12, 2021

SELL
$75.51 - $84.79 $54,367 - $61,048
-720 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$74.73 - $90.69 $5.33 Million - $6.46 Million
-71,280 Reduced 99.0%
720 $5.44 Million
Q4 2020

Feb 16, 2021

SELL
$72.61 - $90.2 $1.31 Million - $1.62 Million
-18,000 Reduced 20.0%
72,000 $6.31 Million
Q2 2020

Aug 13, 2020

BUY
$79.55 - $124.22 $6.38 Million - $9.96 Million
80,200 Added 818.37%
90,000 $11.1 Million
Q4 2018

Feb 14, 2019

SELL
$80.14 - $106.07 $3.37 Million - $4.47 Million
-42,100 Reduced 81.12%
9,800 $835,000
Q3 2018

Nov 14, 2018

SELL
$93.92 - $105.72 $469,600 - $528,600
-5,000 Reduced 8.79%
51,900 $5.03 Million
Q2 2018

Aug 14, 2018

BUY
$76.01 - $99.03 $3.08 Million - $4.01 Million
40,500 Added 246.95%
56,900 $5.36 Million
Q1 2018

May 15, 2018

BUY
$77.67 - $92.63 $1.27 Million - $1.52 Million
16,400 New
16,400 $1.33 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Atika Capital Management LLC Portfolio

Follow Atika Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Atika Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Atika Capital Management LLC with notifications on news.